Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Pharmaceuticals (Europe) Ltd.

Division of Vertex Pharmaceuticals Inc.

Latest From Vertex Pharmaceuticals (Europe) Ltd.

Half Of All EU Fast-Track Requests Fail; AZ’s Imfinzi Among Latest

The European Medicines Agency recently denied AstraZeneca’s pre-filing request for accelerated assessment of Imfinzi in Stage III NSCLC, an indication the company is hoping to make its own. It’ll be no consolation that the EMA this year seems to have rejected as many fast-track requests as it has granted.

Europe Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Vertex Pharmaceuticals Inc.
  • Senior Management
  • Iain P Buchanan, VP, Global Bus. Dev.
    Thierry Hercend, MD, PhD, Dir., UK Research
  • Contact Info
  • Vertex Pharmaceuticals (Europe) Ltd.
    Phone: (44) 344873
    5 Cheapside Court
    Sunninghill Rd.
    Ascot, SL5 7RF
    UK
UsernamePublicRestriction

Register